Navigation Links
Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results
Date:12/7/2007

ALACHUA, Fla., Dec. 7 /PRNewswire-FirstCall/ -- Tutogen Medical, Inc. (Amex: TTG), a leading manufacturer of sterile biological implant products made from human (allograft) and animal (xenograft) tissue, will report financial results for the fourth quarter and fiscal-year 2007 ended September 30, 2007 on Monday, December 10, 2007 at 4:30 p.m. ET.

Interested parties can access the call by dialing (888) 408-9532 or (706) 679-5064 or by accessing the web cast at http://www.tutogen.com/investor.aspx. A replay of the call will be available at (800) 642-1687 or (706) 645-9291, conference ID number: 19673685 for 3 days following the call, and the web cast can be accessed at http://www.tutogen.com/investor.aspx for 30 days.

About Tutogen Medical, Inc.

Tutogen Medical, Inc. manufactures sterile biological implant products made from human (allograft) and animal (xenograft) tissue. Tutogen utilizes its Tutoplast Process(R) of tissue preservation and viral inactivation to manufacture and deliver sterile bio-implants used in spinal/trauma, urology, dental, ophthalmology, and general surgery procedures. The Company's Tutoplast(R) products are sold and distributed worldwide by Zimmer Spine and Zimmer Dental, subsidiaries of Zimmer Holdings, Inc., Davol Inc. subsidiary of C.R. Bard Inc., the Mentor Corporation (Mentor), Coloplast Corp., IOP, Inc. and through independent distributors internationally. For more information, visit the Company's Web site at http://www.tutogen.com.

Contacts:

L. Robert Johnston, Jr.
'/>"/>

SOURCE Tutogen Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
3. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... deicing film for radar domes have now refined the ... , The new work by Rice chemist James ... windshields to skyscrapers free of ice and fog while ... The technology was introduced this month in the American ... , The material is made of graphene nanoribbons, ...
(Date:9/16/2014)... MILLBROOK, N.Y. , Sept. 16, 2014  Donald Fresne, ... the appointment of Stephan Vagner , PhD to its ... the University of Toulouse, France , performed ... Germany , and at Inserm, the French institute of ... Inserm and works both at the Curie Institute, Orsay, ...
(Date:9/16/2014)... Md. , Sept. 16, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today the completion of the Company,s ... which highlighted its irritable bowel syndrome (IBS) ... constipation-predominant IBS (C-IBS). In the keynote ...
(Date:9/16/2014)... 16, 2014  LABSCO, the leading specialty sales ... hospitals, physician office laboratories and alternate healthcare settings ... 2014, it will serve as Siemens Healthcare Diagnostics, ... and as a semi-exclusive sales distributor in specified ... United States . LABSCO will be ...
Breaking Biology Technology:Nanoribbon film keeps glass ice-free 2New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3
... Beckman Coulter, Inc. (NYSE: BEC ), ... that simplify, automate and innovate complex biomedical testing, announced ... results. For the fourth quarter, total revenue was ... Diagnostics customers, partially offset by a decline in Life ...
... N.J., Feb. 9 Pharmasset, Inc. (Nasdaq: ... committed to discovering, developing and commercializing novel drugs ... financial results for the fiscal quarter ended December ... million during each of the quarters ended December ...
... Solutia Inc. (NYSE: SOA ) today,announced that Jeffry ... Deutsche Bank Small and Mid Cap Conference at 3:20 p.m.,Eastern ... A live webcast,of the presentation and a replay will be ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081029/AQW096LOGO ) , ...
Cached Biology Technology:Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 2Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 3Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 4Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 5Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 6Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 7Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 8Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 9Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 10Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 11Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 12Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 13Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 14Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 15Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 16Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 17Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 18Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 19Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 20Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 21Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 22Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 23Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 24Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 25Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 26Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 27Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 28Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 29Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 30Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 31Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 32Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 33Pharmasset Reports Fiscal First Quarter 2009 Financial Results 2Pharmasset Reports Fiscal First Quarter 2009 Financial Results 3Pharmasset Reports Fiscal First Quarter 2009 Financial Results 4
(Date:9/16/2014)... This news release is available in Spanish . ... light on mitosis. The study published in the Journal ... molecules and is essential for proper cell division , At ... and dividing. This is the mechanism by which the body ... It involves a fairly complex process known as "mitosis", during ...
(Date:9/16/2014)... spilled 11 million gallons of oil into Alaska,s Prince ... oil spill in the Gulf of Mexico in 2010. ... of Consumer Research , news coverage of environmental disasters ... changes in the way fossil fuels are used. , ... these two events helped to resolve many of the ...
(Date:9/16/2014)... , Sept. 16, 2014  Valencell, Inc., a leader ... as one of 18 "Showcase Companies" representing ... the annual CED Tech Venture Conference on September 16-17 ... Convention Center in Raleigh, North Carolina ... lead a discussion during the "Digital Health Spotlight Sector" ...
Breaking Biology News(10 mins):Unraveling cell division 2Unraveling cell division 3Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2
... reasons for mass strandings of whales and dolphins, in ... themselves up onto a beach, apparently intentionally. Recent genetic ... play a role in these enigmatic and often fatal ... regarding the reason for strandings is that "care-giving behavior," ...
... prairie around Alberta,s Drumheller area was once a lush ... inland sea, with loads of wetlands inhabited by dinosaurs, ... changed about 71-million-years ago, according to a new study ... at the University of Calgary. The researchers, calculations show ...
... of the Deadliest Pathogens , Francisella tularensis , ... pathogens in existence, is considered a potential biological weapon because ... infectivity and lethality in humans. While a live attenuated ... have been unable to understand the basis for its attenuated ...
Cached Biology News:Oh mother, where art thou? 2Oh mother, where art thou? 3Dinosaur-era climate change study suggests reasons for turtle disappearance 2News tips from the journal mBio®, volume 4, issue 1 2
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Shh Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
... to Asparagine synthetase ( Abpromise ... Antigen: ... in the C-terminus of Human ... Entrez GeneID: 440 ...
Biology Products: